Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-2
NCT05512377Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of brigimadlin in biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma, Urothelial Bladder Cancer (UBC), sponsored by Boehringer Ingelheim. Started Dec 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
biliary tract adenocarcinomapancreatic ductal adenocarcinoma (PDAC)lung adenocarcinomaUrothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT05512377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512377.